Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...

We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against the other hot stocks. What’s the US Stock Market Like in 2025? While the stock market in the ...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the development and commercialization of Vertex’s povetacicept (pove) in ...

Zai Lab Limited is transitioning from a "Hold" to a "Buy" rating due to rapid revenue growth and upcoming potential approvals. ZLAB's strategy involves in-licensing U.S.-approved drugs for the ...

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered ...